View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
July 21, 2011

Tobira Combination Therapy Shows Promising Results

A Tobira Therapeutics Phase I study of cenicriviroc in combination with tenofovir disoproxil fumarate has demonstrated promising results in healthy adults. Cenicriviroc is a potent antagonist of CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor involved in the inf

By cms admin

A Tobira Therapeutics Phase I study of cenicriviroc in combination with tenofovir disoproxil fumarate has demonstrated promising results in healthy adults.

Cenicriviroc is a potent antagonist of CCR5, a co-receptor required for HIV infection, and CCR2, a co-receptor involved in the inflammation process.

The open-label, single-dose, randomised, cross-over Phase I study assessed the pharmacokinetics, safety and tolerability of cenicriviroc and tenofovir disoproxil fumarate when co-administered in healthy adults.

Drug development / regulatory affairs senior vice-president David Martin said that the data showed that the co-administration of cenicriviroc with tenofovir disoproxil fumarate in healthy adult volunteers did not substantially affect the bioavailability of either drug, thus supporting co-administration as part of HIV treatment regimens in future controlled clinical trials.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology